View : 1335 Download: 0

Full metadata record

DC Field Value Language
dc.contributor.author김경효*
dc.date.accessioned2019-07-29T16:31:07Z-
dc.date.available2019-07-29T16:31:07Z-
dc.date.issued2018*
dc.identifier.issn0022-1899*
dc.identifier.issn1537-6613*
dc.identifier.otherOAK-22590*
dc.identifier.urihttps://dspace.ewha.ac.kr/handle/2015.oak/250291-
dc.description.abstractBackground. A 9-valent human papillomavirus-6/11/16/18/31/33/45/52/58 (9vHPV) vaccine extends coverage to 5 next most common oncogenic types (31/33/45/52/58) in cervical cancer versus quadrivalent HPV (qHPV) vaccine. We describe efficacy, immunogenicity, and safety in Asian participants (India, Hong Kong, South Korea, Japan, Taiwan, and Thailand) from 2 international studies: a randomized, double-blinded, qHPV vaccine-controlled efficacy study (young women aged 16-26 years; NCT00543543; Study 001); and an immunogenicity study (girls and boys aged 9-15 years; NCT00943722; Study 002). Methods. Participants (N = 2519) were vaccinated at day 1 and months 2 and 6. Gynecological samples (Study 001 only) and serum were collected for HPV DNA and antibody assessments, respectively. Injection-site and systemic adverse events (AEs) were monitored. Data were analyzed by country and vaccination group. Results. 9vHPV vaccine prevented HPV-31/33/45/52/58-related persistent infection with 90.4%-100% efficacy across included countries. At month 7, >= 97.9% of participants seroconverted for each HPV type. Injection-site AEs occurred in 77.7%-83.1% and 81.9%-87.5% of qHPV and 9vHPV vaccine recipients in Study 001, respectively, and 62.4%-85.7% of girls/boys in Study 002; most were mild to moderate. Conclusions. The 9vHPV vaccine is efficacious, immunogenic, and well tolerated in Asian participants. Data support 9vHPV vaccination programs in Asia.*
dc.languageEnglish*
dc.publisherOXFORD UNIV PRESS INC*
dc.subject9vHPV*
dc.subjectAsia*
dc.subjectcervical cancer*
dc.subjecthuman papillomavirus*
dc.subjectvaccine*
dc.titleEfficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries*
dc.typeArticle*
dc.relation.issue1*
dc.relation.volume218*
dc.relation.indexSCIE*
dc.relation.indexSCOPUS*
dc.relation.startpage95*
dc.relation.lastpage108*
dc.relation.journaltitleJOURNAL OF INFECTIOUS DISEASES*
dc.identifier.doi10.1093/infdis/jiy133*
dc.identifier.wosidWOS:000434930900012*
dc.identifier.scopusid2-s2.0-85048443828*
dc.author.googleGarland, S. M.*
dc.author.googlePitisuttithum, P.*
dc.author.googleNgan, H. Y. S.*
dc.author.googleCho, C-H*
dc.author.googleLee, C-Y*
dc.author.googleChen, C-A*
dc.author.googleYang, Y. C.*
dc.author.googleChu, T-Y*
dc.author.googleTwu, N-F*
dc.author.googleSamakoses, R.*
dc.author.googleTakeuchi, Y.*
dc.author.googleCheung, T. H.*
dc.author.googleKim, S. C.*
dc.author.googleHuang, L-M*
dc.author.googleKim, B-G*
dc.author.googleKim, Y-T*
dc.author.googleKim, K-H*
dc.author.googleSong, Y-S*
dc.author.googleLalwani, S.*
dc.author.googleKang, J-H*
dc.author.googleSakamoto, M.*
dc.author.googleRyu, H-S*
dc.author.googleBhatla, N.*
dc.author.googleYoshikawa, H.*
dc.author.googleEllison, M. C.*
dc.author.googleHan, S. R.*
dc.author.googleMoeller, E.*
dc.author.googleMurata, S.*
dc.author.googleRitter, M.*
dc.author.googleSawata, M.*
dc.author.googleShields, C.*
dc.author.googleWalia, A.*
dc.author.googlePerez, G.*
dc.author.googleLuxembourg, A.*
dc.contributor.scopusid김경효(35448653000)*
dc.date.modifydate20240301081003*
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

BROWSE